Markets:

Overview

News

Currencies

International

Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

9.045 -0.305 (-3.26%)

Delayed Quote Updated: 10:31 AM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >

Earnings Scheduled For March 12, 2024 ↗

March 12, 2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

Via Benzinga

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

February 28, 2024

From Silence Therapeutics plc

Via Business Wire

Where Silence Therapeutics Stands With Analysts ↗

August 17, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Silence Therapeutics ↗

June 26, 2023

Via Benzinga

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

February 23, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

February 05, 2024

From Silence Therapeutics plc

Via Business Wire

Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday ↗

January 31, 2024

U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.

Via Benzinga

Topics Stocks

The Latest Analyst Ratings for Silence Therapeutics ↗

May 11, 2023

Via Benzinga

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024

From Silence Therapeutics plc

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 13, 2023

Via Benzinga

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

December 01, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

November 14, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Present at Jefferies London Healthcare Conference

November 08, 2023

From Silence Therapeutics plc

Via Business Wire

Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate ↗

November 01, 2023

Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 01, 2023

Via Benzinga

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

November 01, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

September 26, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in September Investor Conferences

September 06, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Second Quarter 2023 Results

August 16, 2023

From Silence Therapeutics plc

Via Business Wire

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

July 11, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports First Quarter 2023 Results

May 16, 2023

From Silence Therapeutics plc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 ↗

May 08, 2023

Via Benzinga

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

May 04, 2023

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

May 01, 2023

From Silence Therapeutics plc

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

April 25, 2023

Tuesday's session saw 286 companies set new 52-week lows.

Via Benzinga

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

April 25, 2023

From Silence Therapeutics plc

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

April 24, 2023

On Monday, 147 stocks made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 21, 2023

During Friday's session, 149 stocks hit new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.